Your browser doesn't support javascript.
loading
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
Gutierrez, Martin; Lam, Wei-Sen; Hellmann, Matthew D; Gubens, Matthew A; Aggarwal, Charu; Tan, Daniel Shao Weng; Felip, Enriqueta; Chiu, Joanne W Y; Lee, Jong-Seok; Yang, James Chih-Hsin; Garon, Edward B; Finocchiaro, Giovanna; Ahn, Myung-Ju; Luft, Alexander; Landers, Gregory A; Basso, Andrea; Ma, Hua; Kobie, Julie; Palcza, John; Cristescu, Razvan; Fong, Lawrence; Snyder, Alexandra; Yuan, Jianda; Herbst, Roy S.
Afiliación
  • Gutierrez M; Hackensack University Medical Center, Hackensack, NJ, USA. martin.gutierrez@hmhn.org.
  • Lam WS; Fiona Stanley Hospital and Western Australia Country Health Service, Perth, WA, Australia.
  • Hellmann MD; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Gubens MA; Oncology Research and Development, AstraZeneca, New York, NY, USA.
  • Aggarwal C; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  • Tan DSW; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Felip E; National Cancer Centre and SingHealth Duke NUS Academic Medical Centre, Singapore, Singapore.
  • Chiu JWY; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Lee JS; University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong Kong, China.
  • Yang JC; Seoul National University, Bundang Hospital, Seongnam, South Korea.
  • Garon EB; National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei City, Taiwan.
  • Finocchiaro G; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Ahn MJ; IRCCS Humanitas Research Hospital, Milan, Italy.
  • Luft A; Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, South Korea.
  • Landers GA; Leningrad Regional Clinical Hospital, Saint Petersburg, Russia.
  • Basso A; The Oncology Centre, KwaZulu-Natal, South Africa.
  • Ma H; Merck & Co., Inc., Rahway, NJ, USA.
  • Kobie J; Merck & Co., Inc., Rahway, NJ, USA.
  • Palcza J; Biostatistics, Pfizer, Collegeville, PA, USA.
  • Cristescu R; Merck & Co., Inc., Rahway, NJ, USA.
  • Fong L; Merck & Co., Inc., Rahway, NJ, USA.
  • Snyder A; Merck & Co., Inc., Rahway, NJ, USA.
  • Yuan J; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
  • Herbst RS; Merck & Co., Inc., Rahway, NJ, USA.
Nat Med ; 29(7): 1718-1727, 2023 07.
Article en En | MEDLINE | ID: mdl-37429923
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos